Aktis Oncology Initiates Second Phase 1b Clinical Trial for AKY-2519, a Miniprotein Radioconjugate Targeting B7-H3
Key Highlights
- ➤Phase 1b BActinium-2 trial begins evaluating AKY-2519 in NSCLC and other B7-H3 tumors
- ➤AKY-2519 BActinium-1 trial continues enrolling mCRPC patients
- ➤Preliminary BActinium-1 data expected in 2027
- ➤BActinium-2 trial will explore three dose levels
Expert Statements
Akos Czibere, Chief Medical Officer at Aktis
“AKY-2519 has the potential to be a differentiated therapeutic option for patients with B7-H3 expressing solid tumors, as demonstrated by the first-in-human clinical imaging and dosimetry data presented at ASCO earlier this year.”
Akos Czibere, Chief Medical Officer at Aktis
“With both Phase 1b trials of AKY-2519 now underway, we are efficiently generating indication-relevant data in several cancers with large patient populations to evaluate where AKY-2519 can be most effective.”
* Phase 1b BActinium-2 clinical trial is evaluating AKY-2519 in patients with non-small cell lung cancer (NSCLC) and other B7-H3 expressing tumors * Enrollment is ongoing in the Phase 1b BActinium-1 clinical trial of AKY-2519 in metastatic castration-resistant prostate cancer (mCRPC); preliminary data expected in 2027 BOSTON, Oct. 01, 2026 (GLOBE NEWSWIRE) -- Aktis Oncology, Inc. (NASDAQ:AKTS) (“Aktis” or the “Company”), a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large populations, today announced the initiation of the Phase 1b BActinium-2 trial of AKY-2519(1) in patients with NSCLC and other B7-H3 expressing solid tumor types. The BActinium-2 trial is part of Aktis’ clinical development strategy to develop AKY-2519 broadly in several B7-H3 expressing tumors. In May 2026, Aktis initiated the Phase 1b BActinium-1 trial of AKY-2519 in mCRPC patients, with preliminary data expected in 2027.
Get started
Create a free account to read the full story.